Skip to content

US · TELO · BIOTECHNOLOGY

Telomir Pharmaceuticals, Inc. Common Stock (TELO) intrinsic value and stock valuation

$0.36as of 2026-11-21 · Mkt cap 40.57M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Telomir Pharmaceuticals, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values TELO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TELO’s statements →

Telomir Pharmaceuticals, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Miami, FL 33131 telomirpharma.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-10.41M
20212025
Free cash flow
-$-3.69M
20212025
Total equity
$5.91M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-10.54M-$-12.24M-$-3.94M-$-850K-$-140K
Net income-$-10.41M-$-16.53M-$-13.07M-$-850K-$-140K
EPSd-$-328.91K-$-559.58K-$-441.4K-$-28.71K-$-4.73K
Operating cash flow-$-3.69M-$-5.07M-$-3.86M-$-470K-$-120K
Capital expenditure$0.00$0.00-$0.00$0.00-$0.00
Free cash flow-$-3.69M-$-5.07M-$-3.86M-$-470K-$-120K
Total assets$7.34M$1.32M$4.77M$50K$60K
Total debt$470K$90K$100K$580K$0.00
Net debt-$-6.81M-$-1.17M$100K$580K$120K
Total equity$5.91M$640K$3.44M-$-940K-$-80K
Cash and short-term investments$7.29M$1.27M$0.00$0.00$0.00
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$2.44M$2.24M$1.57M$830K$130K
Selling, general and administrative expenses$8.1M$9.64M$600K$20K$10K
Other expenses$0.00$370K$1.77M$0.00$0.00
Operating expenses$10.5M$12.2M$3.94M$850K$140K
Cost and expenses$10.5M$12.2M$3.94M$850K$140K
Interest income$130K$50K$0.00$0.00$0.00
Interest expense$0.00-$-4.34M$1.64M$0.00$0.00
Depreciation and amortization$0.00$12.2M$0.00$850K$140K
Ebitda-$-10.41M$50K-$-11.43M$0.00$0.00
Operating income-$-10.54M-$-12.24M-$-3.94M-$-850K-$-140K
Total other income/expenses, net$130K-$-4.29M-$-9.13M$0.00$0.00
Income before tax-$-10.41M-$-16.53M-$-13.07M-$-850K-$-140K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-10.41M-$-16.53M-$-13.07M-$-850K-$-140K
Weighted average shares outstanding$31.7M$29.5M$29.6M$29.6M$29.6M
Weighted average diluted shares outstanding$31.7M$29.5M$29.6M$29.6M$29.6M
Balance sheet
20252024202320222021
Cash and short-term investments$7.29M$1.27M$0.00$0.00$0.00
Net receivables$0.00$0.00$130K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$7.34M$1.32M$440K$50K$0.00
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$60K
Total non-current assets$0.00$0.00$4.34M$0.00$60K
Total assets$7.34M$1.32M$4.77M$50K$60K
Accounts payable$540K$590K$710K$400K$20K
Short-term debt$470K$90K$100K$580K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.43M$680K$1.34M$990K$140K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00-$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$1.43M$680K$1.34M$990K$140K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-41.01M-$-30.6M-$-14.06M-$-990K-$-140K
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.91M$640K$3.44M-$-940K-$-80K
Total investments$0.00$0.00$0.00$0.00$60K
Total debt$470K$90K$100K$580K$0.00
Net debt-$-6.81M-$-1.17M$100K$580K$120K
Cash flow statement
20252024202320222021
Net income-$-10.41M-$-16.53M-$-13.07M-$-850K-$-140K
Depreciation and amortization$0.00$4.34M$0.00$0.00$0.00
Stock-based compensation$5.29M$6.87M$0.00$0.00$0.00
Change in working capital$590K$130K$110K$390K$20K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-50K$180K$110K$0.00$20K
Net cash provided by operating activities-$-3.69M-$-5.07M-$-3.86M-$-470K-$-120K
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$9.55M$6.83M$1M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.71M$6.34M$3.86M$470K$120K
Net change in cash$6.02M$1.26M-$0.00$0.00$0.00
Cash at end of period$7.29M$1.27M$0.00$0.00$0.00
Operating cash flow-$-3.69M-$-5.07M-$-3.86M-$-470K-$-120K
Capital expenditure$0.00$0.00-$0.00$0.00-$0.00
Free cash flow-$-3.69M-$-5.07M-$-3.86M-$-470K-$-120K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Telomir Pharmaceuticals, Inc. Common Stock

        Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.

        CEO
        Erez Aminov
        Employees
        2
        Beta
        -0.24

        Explore

        Frequently asked questions

        What is the intrinsic value of Telomir Pharmaceuticals, Inc. Common Stock (TELO)?

        InvestorsCraft does not currently publish an intrinsic value for TELO. How the IC value is calculated.

        Is TELO undervalued?

        InvestorsCraft does not publish an undervaluation signal for TELO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.